Top 10 GLP-1 Skin-Change Questions from Reddit, Answered

Question 1

What is "Ozempic face" and is it actually caused by the drug?

Accepted Answer

Ozempic face is the social-media shorthand for the gaunt, hollowed appearance some patients develop after rapid weight loss on a GLP-1. It is not a drug-specific dermatologic syndrome; it is the same facial fat-pad volume loss that follows any rapid and substantial weight loss, including bariatric surgery and severe caloric restriction. A 2024 systematic review of soft-tissue facial changes after massive weight loss documented that the malar, temporal, periorbital and submental fat compartments lose volume in proportion to total weight loss, with similar patterns across medical and surgical bariatric interventions (Jafar 2024, PMID 39346804). A 2025 Google Trends analysis found search interest in facial volume restoration procedures rose in step with GLP-1 prescribing volume, suggesting public perception is tracking a real anatomical change (Mnajjed 2025, PMID 41255744). The pivotal trials provide the magnitude context: STEP 1 showed mean weight loss of 14.9% on semaglutide 2.4 mg (Wilding 2021, PMID 33567185) and SURMOUNT-1 showed 20.9% on tirzepatide 15 mg (Jastreboff 2022, PMID 35658024). The face thins because the fat pads thin, not because the molecule targets the face. None of this is medical advice.

Question 2

Is loose skin after GLP-1 weight loss permanent?

Accepted Answer

It can be, depending on how much weight you lost, how fast, how old you are and what your skin elasticity looked like to begin with. The post-bariatric literature is the most useful comparator because it describes the same magnitude of weight loss now achievable with GLP-1 drugs. A histological study comparing post-bariatric patients with non-bariatric weight-loss patients found that massive weight loss produces measurable changes in dermal collagen and elastin organization, with reduced elasticity that does not fully recover with time alone (Hany 2024, PMID 38277086). A 2022 review of post-bariatric body contouring concluded that excess redundant skin after massive weight loss is the rule rather than the exception, particularly in patients losing more than 50 pounds, and that surgical excision is the only intervention with reliable evidence for substantial improvement (Sadeghi 2022, PMID 35893406). A 2026 comprehensive review of GLP-1 effects on skin quality reached similar conclusions for the medical weight-loss population (Barone 2026, PMID 42162206). Younger patients and those who lose weight more slowly tend to retain more skin recoil. The decision about plastic surgery is typically deferred until weight has been stable for at least 6-12 months. None of this is medical advice.

Question 3

Does losing weight more slowly actually reduce loose skin?

Accepted Answer

Probably yes, based on indirect evidence, though no head-to-head trial has tested fast versus slow GLP-1 dose escalation specifically for skin-laxity outcomes. The mechanistic logic is consistent across the dermatology and plastic surgery literature: skin remodels through collagen and elastin turnover, both of which operate on a months-to-years timescale. When fat-pad loss outpaces dermal remodeling, the skin envelope ends up larger than the underlying tissue it now contains. A 2024 histological comparison of post-bariatric and non-bariatric weight loss patients found that the speed and magnitude of loss were the strongest predictors of dermal disorganization (Hany 2024, PMID 38277086). A 2026 GLP-1 skin-quality review reached the same conclusion for medical weight loss: faster loss produces more visible laxity (Barone 2026, PMID 42162206). For context, STEP 1 produced 14.9% loss over 68 weeks (Wilding 2021, PMID 33567185), while SURMOUNT-1 produced 20.9% over 72 weeks (Jastreboff 2022, PMID 35658024). Practical implications: extending the dose-escalation interval, or maintaining at a lower dose, may slow the rate enough to give the skin more remodeling time. This is a trade-off conversation worth having with the prescriber. None of this is medical advice.

Question 4

Do GLP-1 drugs cause new stretch marks?

Accepted Answer

The drugs do not appear to cause stretch marks directly; rapid changes in body size do. Striae distensae form when the dermal extracellular matrix cannot keep pace with mechanical strain from rapid expansion or contraction of the underlying tissue. They are most commonly associated with pregnancy, puberty, rapid weight gain and rapid weight loss, regardless of the cause. A 2026 GLP-1 skin-quality literature review noted that striae formation tracks with weight-change velocity in the published case series rather than with specific GLP-1 exposure (Barone 2026, PMID 42162206). Existing stretch marks may also become more visible after weight loss as overlying fat thins, even when no new striae have formed. The cosmetic dermatology literature finds modest improvement from topical interventions like tretinoin and laser therapy for early red striae rubrae, with diminishing returns once marks turn white (striae albae) (Cantelli 2021, PMID 33934473). Microneedling and combination protocols have been studied in small confocal-microscopy series (Mazzella 2019, PMID 30130428). For most patients, the practical answer is that new striae during rapid GLP-1 loss are common and largely cosmetic, and prevention strategies tied to slower loss may be more useful than treatment after the fact. None of this is medical advice.

Question 5

Why does my skin feel so dry on Zepbound or Wegovy?

Accepted Answer

Several mechanisms are plausible and the published evidence does not yet settle which dominates in individual patients. Reduced overall fluid intake is common during GLP-1 therapy because thirst cues, like hunger cues, are blunted alongside the appetite suppression. Reduced food intake also lowers intake of fat-soluble vitamins (A, D, E) and essential fatty acids that support skin barrier function. A 2026 comprehensive literature review of GLP-1 effects on skin quality noted dry skin and reduced skin hydration as recurring observations in case series and clinical reports, with the proposed mechanisms including reduced subcutaneous fat-pad volume, altered sebum production and reduced overall nutritional intake (Barone 2026, PMID 42162206). A 2026 dermatologic-therapy efficacy study evaluated a topical regimen used pre- and post-ultrasound procedures in GLP-1 patients and is one of the first dedicated treatment studies in this population (Moradi 2026, PMID 41781778). Practical countermeasures supported by general dermatology: aim for consistent water intake, prioritize protein and essential fats in the diet, use a ceramide-containing moisturizer twice daily, and avoid hot showers that further strip the skin barrier. None of this is medical advice.

Question 6

Will fillers fix Ozempic face?

Accepted Answer

Fillers can restore lost facial volume, but they treat the appearance rather than the underlying mechanism, which is loss of structural fat in the malar, temporal and periorbital compartments. The 2024 systematic review of soft-tissue facial changes after massive weight loss documented that volume loss is the dominant driver of the gaunt appearance, with skin laxity playing a secondary role (Jafar 2024, PMID 39346804). A 2025 Plastic and Reconstructive Surgery Global Open analysis of Google Trends data showed rising public interest in facial volume restoration procedures correlating with GLP-1 prescribing volume (Mnajjed 2025, PMID 41255744). A 2025 case-series style report described hyperdilute Radiesse used to preserve facial volume in GLP-1 users undergoing rapid weight loss (Durairaj 2025, PMID 41127050). A 2025 review of poly-L-lactic acid in aesthetic dermatology highlighted regenerative biostimulation as a complementary approach to pure volume replacement (Haykal 2025, PMID 40580932). Most clinicians recommend waiting until weight has stabilized for at least 3-6 months before injecting, because ongoing fat loss can leave fillers in unintended positions. None of this is medical advice and product, dose and technique decisions belong with a board-certified dermatologist or plastic surgeon.

Question 7

How long should I wait after stopping a GLP-1 to consider plastic surgery for loose skin?

Accepted Answer

Most post-bariatric and post-weight-loss body-contouring protocols recommend waiting until weight has been stable for at least 6-12 months before evaluating for surgery, and the same logic carries over to GLP-1 patients. A 2022 review of post-bariatric body contouring described abdominoplasty as the most-studied procedure and emphasized weight stability as a prerequisite for both candidacy and durability of results (Sadeghi 2022, PMID 35893406). The rationale is that ongoing weight loss after surgery produces new redundant skin that the original excision did not account for, while weight regain stretches the surgical closure and can compromise aesthetic outcome. Common procedures performed after massive weight loss include abdominoplasty, brachioplasty for upper-arm skin (Szymanski 2026, PMID 36256762), thigh lift and mastopexy. A 2022 review of mechanical thromboprophylaxis in body-contouring patients also noted elevated venous thromboembolism risk in the post-massive-weight-loss population, which is a relevant pre-operative consideration (Petersen 2022, PMID 34268591). The 2024 SCALE trial of liraglutide 3.0 mg established the long-term tolerability template for medical weight-loss maintenance (Pi-Sunyer 2015, PMID 26132939), which is relevant because durable weight maintenance after GLP-1 discontinuation is required for surgical candidacy. None of this is medical advice.

Question 8

Can I prevent loose skin with strength training and protein?

Accepted Answer

You cannot prevent loose skin entirely after substantial weight loss, but you can change the underlying ratio of lean mass to remaining fat, which changes how the result looks. The mechanism is straightforward: weight loss on a GLP-1 includes a meaningful lean-mass component. In STEP 1, mean weight loss was 14.9% with a notable share of that coming from lean tissue (Wilding 2021, PMID 33567185). SURMOUNT-1 with tirzepatide 15 mg produced 20.9% loss with a similar lean-mass concern (Jastreboff 2022, PMID 35658024). Adding resistance training during weight loss preserves more skeletal muscle, which fills the under-skin envelope and produces a less hollowed appearance, particularly in the arms, thighs and abdomen. The standard bariatric counter-measures apply: aim for 1.2-1.6 g/kg/day of protein, train each major muscle group 2-3 times per week, and prioritize compound lifts. This does not prevent the dermal-elasticity changes documented in post-bariatric histological studies (Hany 2024, PMID 38277086), but it does reduce the visual extent of redundant skin. A 2026 GLP-1 skin-quality review reached compatible conclusions for the medical weight-loss population (Barone 2026, PMID 42162206). None of this is medical advice.

Question 9

Are puffy or hollow under-eye changes from GLP-1 a real thing?

Accepted Answer

Yes, and the published dermatology literature is starting to catch up with the Reddit discussion. A 2025 Journal of Clinical Medicine review specifically catalogued functional and aesthetic periorbital, ocular adnexal and ocular surface changes linked to GLP-1 receptor agonists, noting hollowing of the upper eyelid sulcus, increased prominence of the tear-trough deformity and changes in skin quality around the eyes (Kapantais 2025, PMID 41464694). The mechanism is the same fat-pad volume loss that produces the broader Ozempic face appearance: the periorbital fat compartments thin as overall adipose tissue declines, and the resulting hollowing makes the under-eye area look both more sunken and, by contrast, more puffy in the lower lid where the orbital fat pads now protrude through thinned skin. A 2026 GLP-1 skin-quality literature review documented similar periorbital findings (Barone 2026, PMID 42162206). Dry-eye symptoms have also been described in the same population and may share the reduced-overall-hydration mechanism that drives the broader dry-skin complaint. Treatment options include filler in the tear trough, surgical lower-lid blepharoplasty after weight stabilizes, and conservative measures like cold compresses and adequate sleep. None of this is medical advice.

Question 10

Should I stop my GLP-1 because of the skin changes?

Accepted Answer

Stopping is one option, but it is rarely the most informed one and often does not solve the problem. The 2026 comprehensive GLP-1 skin-quality review noted that the dominant skin changes (laxity, volume loss, dryness, stretch marks) are downstream consequences of rapid weight loss rather than direct drug toxicity (Barone 2026, PMID 42162206). The 2024 systematic review of facial soft-tissue changes after massive weight loss reached the same conclusion for the facial appearance specifically (Jafar 2024, PMID 39346804). Stopping the drug abruptly typically leads to weight regain, which fills back some of the volume but creates its own metabolic and psychological costs, and does not restore dermal elasticity once it has changed. Reasonable middle-ground options that many clinicians use: extend the interval between dose escalations to slow the rate of loss, maintain at a lower dose rather than escalating to maximum, add resistance training and adequate protein to preserve lean mass under the skin envelope, optimize hydration and skincare, and consider aesthetic procedures (fillers, biostimulators, surgery) only after weight has stabilized for at least 6-12 months. The SCALE Obesity trial of liraglutide established the long-term tolerability profile that supports staying on therapy through these adjustments (Pi-Sunyer 2015, PMID 26132939). None of this is medical advice and the decision belongs with the patient and prescriber.

Questions and answers